Logo
Whalesbook
HomeNewsCorporate NewsPremiumStocks
HomeNewsCorporate NewsPremiumStocks

Epigral Ltd

₹ 1,167-1.93%
06 Jan – close price
🔗epigral.com•BSE: 543332•NSE: EPIGRAL
Market Cap₹ 5,033 Cr.
Current Price₹ 1,167
High / Low₹ 2,114
Stock P/E12.5
Book Value₹ 487
Dividend Yield0.51 %
ROCE24.9 %
ROE22.3 %
Face Value₹ 10.0
Sales₹ 2,467 Cr.
OPM26.4 %
Mar Cap₹ 5,033 Cr.

ABOUT

Epigral Limited, formerly known as Meghmani Finechem Ltd, incorporated in 2007, is a leading integrated manufacturer of chemicals in India. Epigral’s Dahej facility is a backward and forward integrated and automated complex with a well-planned infrastructure.In India, Epigral is the first to set up an Epichlorohydrin plant and largest capacity plant of CPVC Resin. Epigral is also a leading manufacturer of Caustic Soda, Caustic Potash, Chloromethanes, Hydrogen Peroxide, Chlorine and Hydrogen.

KEY POINTS

Product Segmentsa. Derivatives & Speciality Chemicals (56% in H1 FY25 vs 25% in FY22):[1][2]The company is the5th largest producer of Chloromethanes (CMS) in India, its CMS portfolio includes MDC, Chloroform and CTC. It is also3rd largest producer of Hydrogen Peroxide in India.[3]It also produces specialty chemicals like CPVC Resin, CPVC compound, Epichlorohydrin, Chlorotoluenes Value Chain, etc.[4]

Also present in buckets:
Aggressive Growth TriggersRevenue GuidanceAsset Base ExpansionCapacity Expansion And ProductsCredit Rating UpdatesRed Flags And Poor Performance

Peer Comparision

S.No.NameCurrent Price (Rs.)Price to EarningMarket Capitalization (Rs.Cr.)Dividend yield (%)Net Profit latest quarter (Rs.Cr.)YOY Quarterly profit growth (%)Sales latest quarter (Rs.Cr.)YOY Quarterly sales growth (%)Return on capital employed (%)Sales (Rs.Cr.)OPM (%)Profit after tax (Rs.Cr.)Profit after tax latest quarter (Rs.Cr.)Price to book valueReturn on assets (%)Debt to equity
1.Pidilite Inds.1505.0068.24153165.960.66584.608.363554.449.8829.8413817.5923.312244.67579.2316.0316.220.05
2.Gujarat Fluoroch3492.4056.4238364.010.09179.0047.931210.001.859.894864.0026.89680.00179.005.045.510.23
3.Navin Fluo.Intl.5751.0066.3729472.500.21148.37152.24758.4246.2611.682790.9627.91444.09148.378.186.270.33
4.Deepak Nitrite1625.5041.7222170.690.46118.75-38.871901.89-6.4016.287874.8611.16531.41118.714.029.860.23
5.Atul6182.5033.5718202.370.40182.3731.011551.8511.4212.815898.3216.11542.25179.243.087.480.03
6.BASF India3898.0043.8616872.740.51101.05-21.023904.04-8.0918.0214603.554.17384.69101.054.426.070.04
7.Vinati Organics1614.8036.0116739.930.46129.0221.59546.27-1.2720.612258.6529.70464.92129.025.6413.640.00
8.Epigral1166.7012.525033.300.5151.52-36.02587.36-6.1824.882466.7726.42402.0951.522.4011.840.26
–Median: 92 Co.292.4828.49878.140.327.343.25134.385.6115.16512.2213.0926.077.352.767.880.11

Quarterly Results

Standalone figures in ₹ crores

Dec 2022Dec 2023Dec 2024Jun 2023Jun 2024Jun 2025Mar 2023Mar 2024Mar 2025Sep 2022Sep 2023Sep 2024Sep 2025
Sales
538472645455651607562525628556478626587
Expenses
371349463360475443407369454375370448455
Operating Profit
16712318395176163155155173180108178132
Other Income
-0242285232162
Profit before tax
11474154481311071101131311425612470
Tax %
33%34%33%33%34%-50%30%32%34%35%32%35%26%
Net Profit
7749104328616077778792388152
EPS in Rs
18.5811.8724.007.6220.7037.1818.4818.4520.0822.049.1819.3811.94

Profit & Loss

Standalone Figures in ₹ Crores / Yearly

Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales
3943925987106118291,5512,1881,9292,5502,467
Expenses
2452483464054165671,0411,4991,4481,8391,815
Operating Profit
149144252306194261510689481711652
Other Income
21816224861517
Interest
191492511294466735357
Depreciation
44555554447486109124133151
Profit before tax
8875195242141161383523291540461
Net Profit
6767155183112101253353196357402
EPS in Rs
9.499.4021.9744.3827.1924.4860.8485.0447.1282.6893.20
Dividend Payout %
0%0%0%0%0%0%0%6%11%7%–

Compounded Profit Growth

10 Years:%
5 Years:26%
3 Years:12%
TTM:37%

Compounded Sales Growth

10 Years:%
5 Years:33%
3 Years:18%
TTM:9%

Return on Equity

10 Years:%
5 Years:27%
3 Years:25%
Last Year:22%

Stock Price CAGR

10 Years:%
5 Years:%
3 Years:-1%
1 Year:-37%

Balance Sheet

Standalone figures in ₹ crores

Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital
7171714142424242424343
Reserves
2242914472413314326841,0281,2131,8602,057
Borrowings
19012374601737753993879964593537
Other Liabilities
554279162164223405484576655598
Total Liabilities
5405276711,0441,2731,4492,1242,4322,7943,1513,235
Fixed Assets
3643983472954401,1021,0681,8041,7672,2382,176
Gross Block
408.31497.42497.56499.11688.311,423.691,474.542,319.702,405.812,953.09–
Accumulated Depreciation
44.0599.48150.35204.39248.13321.38406.71515.65639.17715.07–
CWIP
6937946869112658915848364309
Investments
02971000021219744
Other Assets
10698173281142221467449524752707
Total Assets
5405276711,0441,2731,4492,1242,4322,7943,1513,235

Cash Flows

Standalone Figures in ₹ Crores / Yearly

Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity
––––165229284626398441
Cash from Investing Activity
––––-363-197-455-437-401-262
Cash from Financing Activity
––––69-32195-200-8-164
Net Cash Flow
––––-129124-11-1115

Ratios

Standalone Figures in ₹ Crores / Yearly

Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days
43414740465260283433
Inventory Days
755945586451746990105
Days Payable
31375152626942366350
Cash Conversion Cycle
86634246483492616188
Working Capital Days
434019-27-76-92-26-41-5426
ROCE %
–18%37%36%15%16%29%32%17%25%

Shareholding Pattern

Numbers in percentages

Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
Promoters
71.21%71.34%71.37%71.38%71.38%71.49%71.58%71.58%68.94%68.95%68.83%68.83%
FIIs
1.15%1.20%1.16%1.14%1.17%1.36%1.46%2.10%3.01%3.01%3.06%2.71%
DIIs
0.17%0.03%0.04%0.04%0.05%0.02%0.18%1.17%4.31%4.66%4.78%4.93%
Public
27.44%27.39%27.39%27.40%27.37%27.10%26.75%25.12%23.71%23.34%23.30%23.52%

* The classifications might have changed from Sep'2022 onwards.ℹ️

BSE Announcements AI Summary

Direct from BSE filings, auto-summarised

Epigral Board Approves Re-appointment of 3 Independent Directors

16th April 2026, 10:37 pm

Epigral Limited to Host Investor & Analyst Meeting on April 13, 2026

9th April 2026, 8:33 pm

Epigral Limited to Hold Investor Meeting with Dhamma Capital on April 10, 2026

9th April 2026, 8:25 pm

Epigral Limited Submits SEBI Compliance Certificate for March 2026 Quarter

8th April 2026, 6:54 pm

Epigral Limited Announces Non-Deal Roadshow with Institutional Investors

4th April 2026, 5:26 pm

Published by Other Websites

External media mentions & references

Middle East Conflict Fuels Indian Chemical Sector Volatility

5th March 2026, 2:25 pm

India's Specialty Chemicals: Uncovering Hidden Value in Mid-Caps

4th March 2026, 5:39 am

Major Firms Reveal Q3 Results Jan 30: NTPC, BoB, Bajaj Auto Estimates

29th January 2026, 11:38 pm

Smallcaps Skyrocket! 50+ Stocks Jump 10-34% As Indian Markets Outperform!

27th December 2025, 2:42 pm

Bullish Turnaround! Dalal Street Surges as Sensex & Nifty Rebound Sharply

19th December 2025, 1:33 pm

News Articles

Editorial & research coverage

Smallcaps Skyrocket! 50+ Stocks Jump 10-34% As Indian Markets Outperform!
Smallcaps Skyrocket! 50+ Stocks Jump 10-34% As Indian Markets Outperform!

27th December 2025, 2:42 pm

Bullish Turnaround! Dalal Street Surges as Sensex & Nifty Rebound Sharply
Bullish Turnaround! Dalal Street Surges as Sensex & Nifty Rebound Sharply

19th December 2025, 1:33 pm

Q2 Earnings Fury: Graphite India & Epigral Crash, Krsnaa Diagnostics Skyrockets! See the Shocking Numbers!
Q2 Earnings Fury: Graphite India & Epigral Crash, Krsnaa Diagnostics Skyrockets! See the Shocking Numbers!

10th November 2025, 5:06 pm

Documents

Announcements

Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order

1 Jan - Assessment order for AY2022-23 demand Rs.52.52 crore received 31/12/2025; company to appeal.

Closure of Trading Window
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

22 Dec - Epigral Limited has informed about One-on-One Meeting through V.C. with Investor / Analyst on 23rd December, 2025

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

28 Nov 2025 - One-on-one VC meeting with HSBC Mutual Fund on 1 Dec 2025; no unpublished price-sensitive information.

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

26 Nov 2025 - Epigral Limited has informed about One-on-One Meeting through V.C. with Investor / Analyst on 1st December, 2025.

Annual Reports

Financial Year 2025

(from bse)

Financial Year 2024

(from bse)

Financial Year 2023

(from bse)

Financial Year 2022

(from bse)

Financial Year 2021

(from bse)

Credit Ratings

Rating update

6 Mar 2025 from crisil

Rating update

16 Dec 2024 from crisil

Rating update

25 Jan 2024 from crisil

Rating update

24 Nov 2023 from crisil

Rating update

7 Dec 2022 from crisil

Rating update

22 Dec 2021 from crisil

Concalls

Nov 2025

TranscriptPPTRecording

Aug 2025

TranscriptPPT

May 2025

TranscriptPPTRecording

Jan 2025

TranscriptPPTRecording

Nov 2024

TranscriptPPT

Jul 2024

TranscriptPPT

Apr 2024

TranscriptPPT

Apr 2024

TranscriptPPTRecording

Apr 2024

PPT

Jan 2024

Transcript

Jan 2024

TranscriptPPTRecording

Jan 2024

PPT

Nov 2023

TranscriptPPTRecording

Sep 2023

PPT

Aug 2023

TranscriptPPT

Aug 2023

PPT

Apr 2023

TranscriptPPTRecording

Jan 2023

TranscriptPPT

Jan 2023

PPT

Oct 2022

TranscriptPPT

Aug 2022

TranscriptPPT

Jul 2022

PPT

Jun 2022

PPT

Apr 2022

TranscriptPPT

Apr 2022

PPT

Jan 2022

TranscriptPPT

Nov 2021

TranscriptPPT

Nov 2021

PPT

Nov 2021

PPT

Oct 2021

PPT

Aug 2021

PPT

Aug 2021

PPT

Stock Analysis

Description

Epigral Limited is a leading integrated manufacturer of chemicals in India, with operations at its Dahej facility. The company produces Caustic Soda, Caustic Potash, Chloromethanes, Hydrogen Peroxide, Chlorine, Hydrogen, and is a pioneer in Epichlorohydrin and CPVC Resin production in India.

Key Growth Triggers

Epigral is strategically expanding its Derivatives & Speciality Chemicals segment, targeting over 70% revenue contribution by FY28. Key products include Chloromethanes and Hydrogen Peroxide. Significant capacity expansions in CPVC Resin and Epichlorohydrin are on schedule for commissioning in H1 FY27, poised to drive future growth.

Order Book

Currently no data available for Order Book.

Key Red Flags

Currently no data available for Key Red Flags.

Key Dates To Watch

  1. January 16, 2026: One-on-one investor meeting with UTI Asset Management Company Ltd.

Corporate Announcements

16th Apr 26
Impact Rating: 5
Epigral Limited has approved the re-appointment of three Non-Executive Independent Directors, each for a second five-year term, effective May 20, 2026.
9th Apr 26
Impact Rating: 4
Epigral Limited will meet with investors and analysts on April 13, 2026, through video conferencing. The company has made its latest presentations available online.
9th Apr 26
Impact Rating: 4
Epigral Limited will meet with investor Dhamma Capital on April 10, 2026, via video conference. Latest company presentations are already available on the website, ensuring no unpublished price-sensitive information is shared.
8th Apr 26
Impact Rating: 4
Epigral Limited has submitted its SEBI Regulation 74(5) compliance certificate for the quarter ended March 31, 2026. The filing confirms that dematerialized securities were processed and physical share certificates were cancelled by the registrar.
4th Apr 26
Impact Rating: 7
Epigral Limited will host a Non-Deal Roadshow on April 8, 2026, in Mumbai, featuring one-on-one meetings with institutional investors to discuss corporate and earnings presentations.